.Pharmacolibrary.Drugs.ATC.L.L02BX02

Information

Degarelix is a selective gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of advanced hormone-dependent prostate cancer in men. It acts by suppressing the production of luteinizing hormone and subsequently testosterone without causing a testosterone surge. Degarelix is currently approved for medical use in many countries for prostate cancer.

Pharmacokinetics

Pharmacokinetic parameters reported in adult males with prostate cancer following subcutaneous administration.

References

1. Tornøe, CW, et al., & Jonsson, EN (2004). Population pharmacokinetic modeling of a subcutaneous depot for GnRH antagonist degarelix. Pharmaceutical research 21(4) 574–584. DOI:10.1023/b:pham.0000022403.60314.51 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15139513

2. Tornøe, CW, et al., & Jonsson, EN (2007). Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues. British journal of clinical pharmacology 63(6) 648–664. DOI:10.1111/j.1365-2125.2006.02820.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/17096678

3. Tornøe, CW, et al., & Jonsson, EN (2005). Stochastic differential equations in NONMEM: implementation, application, and comparison with ordinary differential equations. Pharmaceutical research 22(8) 1247–1258. DOI:10.1007/s11095-005-5269-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16078134

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)